Navigation Links
CSL Behring Partners with Pro Supercross Racer Carl Schlacht to Encourage Those with Primary Immunodeficiency to be a "ChamPIon"
Date:12/13/2012

KING OF PRUSSIA, Pa., Dec. 13, 2012 /PRNewswire/ -- CSL Behring has teamed up with Professional Supercross racer Carl Schlacht to launch www.IamaChamPIon.com. This new online resource is part of the I am a ChamPIon campaign, a partnership that aims to raise awareness of primary immunodeficiency disease (PI or PIDD) while encouraging those with the condition to pursue their dreams despite the challenges that PI can pose. 

"PI is a genetic disorder that can have a dramatic impact on a person's ability to participate in daily activities due to a weakened immune system that leaves him or her vulnerable to common infections. If PI is left untreated, infections can occur – some severe enough to cause permanent and irreversible organ damage," said Dr. John Sleasman, Chief of the Division of Pediatric Allergy, Immunology and Rheumatology at the University of South Florida. "While the condition is not curable, immunoglobulin treatments can help supplement the immune system to allow patients to lead active lives."

Carl is just one of approximately 250,000 individuals (or one in 1,200) diagnosed with PI in the United States. Race fans watching Carl perform high flying jumps and difficult maneuvers would never know that he requires a weekly subcutaneous infusion (i.e., under the skin) of immunoglobulin to manage his condition, which helps him stay healthy to compete at the professional level.

"Growing up I didn't know anyone else affected by primary immunodeficiency," said Carl, who was diagnosed with PI at a year old. "For this reason, I am encouraging everyone affected by PI to visit www.IamaChamPIon.com and post their 'ChamPIon' story. Collectively, we can support and inspire each other to pursue our dreams." 

In addition to providing an outlet for people with PI to share their stories, the I Am a ChamPIon website offers information about the condition and identifying the warning signs for diagnosis. At www.IamaChamPIon.com you can also watch a video of Carl on the race track and discussing his journey to becoming a professional Supercross racer despite PI.  

About Primary Immunodeficiencies   
Nearly 150 types of PIs exist. For individuals with PI, many of them children, infections may not improve as expected with usual treatments and may even keep returning. As a result, patients may face repeated rounds of antibiotics or hospitalization for treatment. Repeated infections can lead to organ damage, which over time can become life-threatening. Some infections, such as meningitis, may even result in death.

Collectively, PIs affect an estimated 10 million people worldwide. Due to the X-linked inheritance in many PI syndromes, more males are affected than females.  For more information on PI, please visit www.IamaChamPIon.com or contact the leading PI patient advocate groups in the U.S., the Immune Deficiency Foundation and the Jeffrey Modell Foundation.

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited  (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.

Media Contacts:
Greg Healy
Senior Manager, Public Relations & Communications
CSL Behring
1-610-878-4841
greg.healy@cslbehring.com

Etanjalie Ayala
Weber Shandwick
212-445-8225
eayala@webershandwick.com

Judy Welage
Weber Shandwick
212-445-8308
jwelage@webershandwick.com


'/>"/>
SOURCE CSL Behring
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care
2. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
3. Medical Experts Who Participated in CSL Behrings Key Issues Dialogue Prefer Albumin for Fluid Management
4. CSL Behring Awards LEAD Grant to Patient Organizations to Educate Constituents on State Insurance Exchanges
5. CoreLab Partners, Medical Image Assessment Experts, Announces Its Entry Into the Early Alzheimers Imaging Market Space
6. Veterinary Bioscience Institute (VBI) and a-tune software, Inc. Partnership
7. Chimerix To Present At Therapeutic Area Partnerships Meeting
8. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
9. Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings
10. Bluechiip Signs Strategic Partnership with Gentris Corporation
11. UBM Announces Partnership Agreement With Trade Organisation - SIPPO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
Breaking Biology News(10 mins):